文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

MR-PROTECT:前列腺MRI-only放疗工作流程的临床可行性及验收标准研究

MR-PROTECT: Clinical feasibility of a prostate MRI-only radiotherapy treatment workflow and investigation of acceptance criteria.
PubMed 文献 · Radiat Oncol · 2020-04-09

MR-PROTECT试验前瞻性实施前列腺癌MRI-only放疗工作流程,采用单一MR序列策略并集成商用合成CT生成软件MriPlanner™。40例患者中39例成功完成MRI-only治疗,PTV平均剂量最大偏差1.2%,gamma通过率高于98%,患者摆位偏差除一例外均小于2mm,金标识别最大偏差2.2mm。研究表明该工作流程临床可行,先前建议的剂量偏差和gamma通过率验收标准可达标。

要点

  • 39/40例患者成功完成MRI-only放疗,1例因成像视野不足排除。
  • 前瞻性CT质控显示PTV平均剂量最大偏差1.2%。
  • gamma通过率高于98%,金标识别最大偏差2.2mm。

核心结论

  • MR-PROTECT试验表明前列腺MRI-only放疗工作流程临床可行,先前建议的剂量偏差和gamma通过率验收标准可达标。

研究设计与样本

  • 前瞻性单臂试验,纳入40例前列腺癌患者,实施包含成像、计划创建、质控和治疗的MRI-only工作流程。
  • 所有任务在单一MR序列几何下完成,消除图像配准,并使用商用合成CT生成软件MriPlanner™。
  • 前瞻性CT质控比较合成CT与CT的PTV平均剂量,回顾性分析金标识别、DVH、gamma评估和患者摆位验证。

主要发现

  • 40例中39例成功实施MRI-only治疗,1例因体型超出预定义成像视野而排除。
  • 前瞻性CT质控中PTV平均剂量最大偏差为1.2%。
  • 回顾性DVH分析在校正直肠气体后最大偏差低于2%,gamma通过率高于98%。
  • MRI-only患者摆位偏差除一例外均低于2mm,金标识别与CT相比最大偏差2.2mm。

关键数值与推荐

  • PTV平均剂量偏差验收标准:前瞻性质控最大偏差1.2%,回顾性DVH分析校正直肠气体后最大偏差低于2%。
  • gamma通过率验收标准:高于98%。
  • 金标识别验收标准取决于识别方法和层厚,患者摆位策略需进一步研究以建立验收标准。

临床怎么用

  • 该单序列MRI-only工作流程易于被其他中心采用,通用实施程序可复制。
  • 合成CT生成方法具有多厂商能力,是工作流程的主要优势。
  • 剂量偏差和gamma通过率验收标准已获确认,可用于临床实施。

局限性

  • 金标识别验收标准取决于识别方法和层厚,尚未统一。
  • 患者摆位策略需进一步研究以建立验收标准。
  • 1例患者因成像视野不足被排除,提示体型较大患者可能不适用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Retrospective studies on MRI-only radiotherapy have been presented. Widespread clinical implementations of MRI-only workflows are however limited by the absence of guidelines. The MR-PROTECT trial presents an MRI-only radiotherapy workflow for prostate cancer using a new single sequence strategy. The workflow incorporated the commercial synthetic CT (sCT) generation software MriPlanner™ (Spectronic Medical, Helsingborg, Sweden). Feasibility of the workflow and limits for acceptance criteria were investigated for the suggested workflow with the aim to facilitate future clinical implementations. METHODS: An MRI-only workflow including imaging, post imaging tasks, treatment plan creation, quality assurance and treatment delivery was created with questionnaires. All tasks were performed in a single MR-sequence geometry, eliminating image registrations. Prospective CT-quality assurance (QA) was performed prior treatment comparing the PTV mean dose between sCT and CT dose-distributions. Retrospective analysis of the MRI-only gold fiducial marker (GFM) identification, DVH- analysis, gamma evaluation and patient set-up verification using GFMs and cone beam CT were performed. RESULTS: An MRI-only treatment was delivered to 39 out of 40 patients. The excluded patient was too large for the predefined imaging field-of-view. All tasks could successfully be performed for the treated patients. There was a maximum deviation of 1.2% in PTV mean dose was seen in the prospective CT-QA. Retrospective analysis showed a maximum deviation below 2% in the DVH-analysis after correction for rectal gas and gamma pass-rates above 98%. MRI-only patient set-up deviation was below 2 mm for all but one investigated case and a maximum of 2.2 mm deviation in the GFM-identification compared to CT. CONCLUSIONS: The MR-PROTECT trial shows the feasibility of an MRI-only prostate radiotherapy workflow. A major advantage with the presented workflow is the incorporation of a sCT-generation method with multi-vendor capability. The presented single sequence approach are easily adapted by other clinics and the general implementation procedure can be replicated. The dose deviation and the gamma pass-rate acceptance criteria earlier suggested was achievable, and these limits can thereby be confirmed. GFM-identification acceptance criteria are depending on the choice of identification method and slice thickness. Patient positioning strategies needs further investigations to establish acceptance criteria.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Persson E, Jamtheim Gustafsson C, Ambolt P, et al. MR-PROTECT: Clinical feasibility of a prostate MRI-only radiotherapy treatment workflow and investigation of acceptance criteria. Radiat Oncol. 2020. PMID: 32272943. doi:10.1186/s13014-020-01513-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。